|
 |
| LETTER TO THE EDITOR |
|
| Year : 2018 | Volume
: 66
| Issue : 2 | Page : 349-350 |
|
Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
Aditya Bansal1, Muna Bhende1, Tarun Sharma1, Pramod Bhende1, Suchetana Mukherjee2
1 Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
2 Vitreoretinal Services, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India
| Date of Web Publication | 30-Jan-2018 |
Correspondence Address:
Muna Bhende
Sankara Nethralaya, 18/41, College Road, Nungambakam, Chennai - 600 006, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijo.IJO_1093_17
How to cite this article:
Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol 2018;66:349-50 |
How to cite this URL:
Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol [serial online] 2018 [cited 2021 Mar 2];66:349-50. Available from: https://www.ijo.in/text.asp?2018/66/2/349/224064 |
Sir,
We thank you for your interest in our paper and agree with your concerns.[1],[2] All the patients were treated at our institute from the beginning. The definition of recalcitrance/resistance has been mentioned in the text. As this is a retrospective analysis of patients followed over many years, some even before the introduction of antivascular endothelial growth factors in ophthalmology, it is not possible for us to fit all the cases into defined criteria for switching agents, stopping, or continuing treatment. The reason for introducing recurrent cases to aflibercept was to ascertain the possibility of achieving an end point in treatment or at least an increase in the treatment-free interval. Failure to achieve either of the two resulted in a switch back to the original drug as long as the eye had useful vision. We agree that financial issues are important which is why our study had only ten patients, those who could afford the injection and not all cases that were resistant or recalcitrant. This particular study was not intended to test the use of either aflibercept or ziv-aflibercept as primary treatment of polypoidal choroidal vasculopathy; hence, we would not like to extrapolate our results in that direction.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | |  |
| 1. | Kathiriya V, Kanhere M, Gala Y, Ramchandani S. Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol 2018;66:348-9.  [Full text] |
| 2. | Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol 2017;65:758-60. [ PUBMED] [Full text] |
|
.png "Santen")
Search Pubmed for